News about "Immune Thrombocytopenia "

EU Approves Sanofi's Wayrilz as First BTK Inhibitor for Immune Thrombocytopenia

EU Approves Sanofi's Wayrilz as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi has received EU approval for Wayrilz, the first Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for immune thrombocytopenia, offering a novel multi-immune modulation approach. The approval is based on positive results from LUNA 3 study, which demonstrated rapid and durable platelet responses.

Immune Thrombocytopenia | 24/12/2025 | By News Bureau

Ouro Medicines Receives US FDA ODD for Gamgertamig (OM336) for Immune Thrombocytopenia

Ouro Medicines Receives US FDA ODD for Gamgertamig (OM336) for Immune Thrombocytopenia

Ouro Medicines has secured a second ODD from the FDA for gamgertamig (OM336), this time for immune thrombocytopenia (ITP), following an earlier designation for autoimmune hemolytic anemia (AIHA). It comes as the company completes dosing in the first cohort of its global basket trial in autoimmune cytopenias.

Immune Thrombocytopenia | 09/12/2025 | By Akanki

CASI Pharmaceuticals Advances CID-103 into Clinical Development for Chronic Immune Thrombocytopenia

CASI Pharmaceuticals Advances CID-103 into Clinical Development for Chronic Immune Thrombocytopenia

CASI received a letter from the FDA indicating clearance for the study to proceed, signaling regulatory approval for the advancement of CID-103 into clinical trials.

Immune Thrombocytopenia | 16/05/2024 | By Abha 536


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members